Phase Forward and Eli Lilly Extend Multi-Year Agreement
Posted on: Thursday, 7 August 2008, 12:01 CDT
Phase Forward, a provider of data management solutions for clinical trials and drug safety, has signed a multi-year extension agreement with Eli Lilly and Company.
Since 2001, Lilly has utilized Phase Forward's InForm product in over 200 trials and plans to continue to use InForm for global trials across all phases, as well as mandating the use of the InForm product with its global service partners.
Jeffrey Kasher, vice president and COO of global clinical development at Eli Lilly, said: "We look forward to continuing to leverage Phase Forward as our clinical data management solution of choice.
"Phase Forward has been a longstanding member of Eli Lilly's Alliance program and has been instrumental in providing Lilly with technology solutions in order to expand our global trials."
Source: Datamonitor
Related Articles
- Reportlinker Adds Innovations and Trends in Clinical Trials: Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
- GTx Announces Investigational Ostarine(TM) (MK-2866) Met the Primary Endpoint in the Phase II Cancer Cachexia Clinical Trial
- Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
- Medicure Announces Top-Line Results From Pivotal Phase 3 MEND-CABG II Clinical Trial
- Critical Outcome Technologies Inc. Announces Intentions to Prepare a Phase 1B Health Canada Clinical Trial Submission
- Third-Party Audit Firm Confirms Lilly Has Kept Its Promise to Disclose Clinical Trial Data
- Oncolytics Biotech Inc. Announces Conclusion of Patient Follow Up in Canadian Phase I Recurrent Malignant Glioma Clinical Trial
- Pro-Pharmaceuticals Receives Clearance From EMEA to Initiate International Phase III Colorectal Cancer Clinical Trial
- PharmaFrontiers Tovaxin(TM) Phase IIb Multiple Sclerosis Clinical Trial Protocol Accepted By FDA
- Manhattan Pharmaceuticals Initiates Patient Dosing in Phase Ib Oleoyl Estrone Clinical Trial
 |
 |
User Comments (0)
RSS Feeds